The authors thank Eastmond Medicomm Ltd and OPEN Health Medical Communications (Choice) for editorial support funded by Boehringer Ingelheim International GmbH.
The trial was sponsored by Boehringer Ingelheim International GmbH & Co. KG, Biberach an der Riss, Germany.
Disclosure: G.E. Lang, Novartis Pharma GmbH (F, C, S), Allergan (C, S), Alcon Pharma GmbH (C, S), Bayer AG (F, S), Boehringer Ingelheim (C, S), Carl Zeiss Meditec (F, S), Alimera Sciences (S); R. Tadayoni, Alcon Laboratories Inc. (C), Alimera Sciences, Inc. (C), Allergan (C), Bausch & Lomb (C), Bayer HealthCare Pharmaceuticals (C), Carl Zeiss Meditec (C), Chibret International (C), FCI Ophthalmics (C), Genentech (C), Moria (C), Novartis (C), Roche (C), ThromboGenics, Inc. (C); W. Tang, Boehringer Ingelheim (E); C. Barth, Boehringer Ingelheim (E); C. Weiss-Haljiti, Boehringer Ingelheim (E); V. Chong, Boehringer Ingelheim (E)